Studies have shown that the enhancement of the PERK–-ATF4–CHOP pathway disrupts the intestinal barrier function and leads to increased intestinal permeability, thereby promoting the development of inflammatory bowel disease and other intestinal-related diseases.30,31 The specific manifestations are: (1) affecting tight junction proteins: the PERK–ATF4–CHOP signaling pathway may affect tight junction proteins, e.g., claudin and occludin, thereby disrupting the completeness of the enteric mechanical barrier and increasing the permeability of the intestinal tract. This evidence concerns the gene ATF4 and inflammatory bowel disease.